{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:00:27Z","timestamp":1782936027172,"version":"3.54.5"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p> Clozapine is gold standard for the management of treatment-resistant schizophrenia. It can offer life-changing symptom reduction where other antipsychotics have failed, and for these patients, treatment with clozapine should be maintained, if in any possible way. However, treatment with clozapine comes with a risk of developing potentially fatal adverse reactions, for example, severe neutropenia or agranulocytosis, in which case, treatment must be discontinued. Here, we present a case of clozapine-related neutropenia that commenced after the addition of sodium valproate. A subsequent re-challenge to clozapine resulted in severe neutropenia and led to the permanent cessation of clozapine treatment. The patient had been tolerating clozapine for more than a year before the addition of sodium valproate. The awareness of an interaction between clozapine and sodium valproate could help reduce the risk of clozapine-induced neutropenia and subsequent clozapine discontinuation. <\/jats:p>","DOI":"10.1177\/2050313x211019791","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T06:57:35Z","timestamp":1622444255000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Clozapine-associated neutropenia following augmentation with sodium valproate"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-9074","authenticated-orcid":false,"given":"Michelle Iris","family":"Jakobsen","sequence":"first","affiliation":[{"name":"Psychiatry East, Region Zealand Psychiatry, Roskilde, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Gr\u00f8nborg","sequence":"additional","affiliation":[{"name":"The Trauma Centre and Acute Admission, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H V","family":"Hansen","sequence":"additional","affiliation":[{"name":"Psychiatric Outpatient Clinic Strandboulevarden, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Fink-Jensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Psychiatric Centre Copenhagen, Rigshospitalet, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,5,30]]},"reference":[{"key":"bibr1-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.177261"},{"key":"bibr2-2050313X211019791","unstructured":"The European Agency for the Evaluation of Medicinal Products. Summary information on referral opinion following arbitration pursuant to article 30 of council directive 2001\/83\/EC for Leponex and associated names, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Leponex_30\/WC500010966.pdf (2002, accessed 12 April 2015)."},{"key":"bibr3-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618756261"},{"key":"bibr4-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11r06977"},{"key":"bibr5-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12898"},{"key":"bibr6-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721010-00003"},{"key":"bibr7-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.08.041"},{"key":"bibr8-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.3.413"},{"key":"bibr9-2050313X211019791","unstructured":"Sanofi-Aventis Australia Pty Ltd. AUSTRALIAN PRODUCT INFORMATION EPILIM\u00ae (SODIUM VALPROATE), https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-05620-3&d=202104111016933 (2020, accessed 14 April 2021)."},{"key":"bibr10-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(02)00659-4"},{"key":"bibr11-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.2001.0911f.x"},{"key":"bibr12-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2004.09.007"},{"key":"bibr13-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000705"},{"key":"bibr14-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.10.014"},{"key":"bibr15-2050313X211019791","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.188.3.255"}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X211019791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X211019791","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X211019791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T18:09:30Z","timestamp":1737742170000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X211019791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":15,"alternative-id":["10.1177\/2050313X211019791"],"URL":"https:\/\/doi.org\/10.1177\/2050313x211019791","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"2050313X211019791"}}